innerbuddies gut microbiome testing

Gut Microbiome and Systemic Lupus Erythematosus (SLE): How Your Microbiome Affects Lupus

Systemic lupus erythematosus (SLE) is an autoimmune condition where the immune system mistakenly targets the body, driving chronic inflammation and potentially affecting the skin, joints, kidneys, and other organs. Increasingly, research suggests that the gut microbiome—the trillions of bacteria and other microbes living in your digestive tract—may help shape how immune responses turn on or calm down. When the gut ecosystem shifts (often termed “dysbiosis”), immune balance can be disrupted, potentially influencing lupus activity.

Your gut microbes produce metabolites (like short-chain fatty acids and other signaling molecules) that act like “biochemical messages” to the immune system. They can affect the gut barrier, train immune tolerance, and influence inflammatory pathways—all of which are closely tied to the immune dysregulation seen in SLE. Studies have reported differences in microbial composition and function in people with lupus compared with healthy controls, and some patterns may correlate with disease activity, flares, and inflammation.

While microbiome research isn’t a substitute for standard lupus care, it offers promising insights into why symptoms can vary and how lifestyle and treatment choices may interact with immune health. By understanding the gut–immune connection, you can better explore evidence-informed strategies—such as diet quality, fiber intake, and (when appropriate) discussion of probiotics or prebiotics with your healthcare team—to support a healthier microbial ecosystem alongside your lupus management plan.

Test Your Gut Microbiome to Support Lupus Health Start Your Gut Microbiome Test for Lupus
innerbuddies gut microbiome testing

Systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system targets the body’s tissues. Growing evidence suggests the gut microbiome influences the degree of immune dysregulation, with gut dysbiosis and altered microbial functions linked to inflammation and autoantibody production. Microbial metabolites such as short-chain fatty acids help maintain gut barrier integrity and support regulatory immune cells, while a leaky gut can amplify systemic immune activation. The relationship is bidirectional: SLE activity and treatments can reshape the microbiome, and diet can further modulate it, making microbiome-informed strategies a potential complement to standard care.

Across studies, SLE-associated dysbiosis shows reduced microbial diversity and shifts in taxa, with losses of beneficial, barrier-supporting bacteria (e.g., Faecalibacterium prausnitzii, Roseburia, Eubacterium rectale, Anaerostipes, Bifidobacterium, and Akkermansia muciniphila) and rises in pro-inflammatory taxa (e.g., Ruminococcus gnavus, Blautia, Prevotella, Enterococcus, Escherichia-Shigella, Dialister). Functional changes in SCFA production and bile acid metabolism may weaken regulatory T cell activity and promote inflammation, helping explain multi-system symptoms such as arthritis, rashes, fatigue, mucosal ulcers, and chest inflammation. Testing the gut microbiome can identify dysbiosis and functional gaps, guiding personalized lifestyle or dietary adjustments, including targeted prebiotic/probiotic approaches when appropriate.

Tools like InnerBuddies emphasize microbial function—focusing on what the microbiome does (metabolic outputs) rather than just who is present—to support gut barrier health and immune regulation in SLE. Given the bidirectional influence of disease activity and medications on the microbiome, such testing can offer actionable context for monitoring responses to fiber-rich diets and other strategies aimed at stabilizing the gut–immune axis alongside conventional lupus therapies.

  • Reduced butyrate-producing taxa (Faecalibacterium prausnitzii; Roseburia spp.; Eubacterium rectale; Anaerostipes spp.) lowers SCFA/butyrate levels, dampens regulatory T cell activity, and weakens gut barrier, promoting systemic inflammation in SLE.
  • Expansion of pro-inflammatory taxa (Ruminococcus gnavus; Prevotella spp.; Escherichia-Shigella) and related metabolic activity heightens pro-inflammatory cytokine signaling and may drive autoimmunity in SLE.
  • Loss of barrier-supporting microbes (Bifidobacterium spp.; Akkermansia muciniphila) compromises the mucus layer and tight junctions, increasing gut permeability and exposure to microbial products.
  • Dysbiosis-associated changes in bile acid metabolism (affecting receptors like FXR and TGR5) disrupt immune regulation and may influence autoantibody dynamics in SLE.
  • Overall dysbiosis shifts metabolic output and signaling toward a sustained inflammatory state (reduced SCFAs, altered bile acids, greater microbial product exposure), contributing to immune dysregulation in SLE.
Test Your Gut Microbiome to Support Lupus Health Start Your Gut Microbiome Test for Lupus
innerbuddies gut microbiome testing

Autoimmune disease

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly targets the body’s own tissues. While genetics and immune signaling are central drivers, growing evidence suggests that the gut microbiome—the community of microorganisms living in the intestines—can influence how strongly the immune system becomes dysregulated. In many people with SLE, researchers have observed gut microbial imbalance (dysbiosis) alongside altered microbial functions, which may affect immune pathways involved in inflammation and autoantibody production.

Gut microbes help regulate the immune system by shaping inflammatory tone, supporting the gut barrier, and producing metabolites such as short-chain fatty acids (SCFAs) and other bioactive compounds. These metabolites can influence regulatory immune cells (like Tregs) and help maintain immune balance. When the gut microbiome is disrupted, the intestinal barrier may become more permeable (“leaky gut”), potentially allowing microbial products to interact more readily with the immune system. This can contribute to chronic inflammation and may amplify the immune dysregulation typical of SLE.

Research is increasingly pointing to a bidirectional relationship: SLE itself (including immune activity, medications like corticosteroids or immunosuppressants, and diet-related changes) can alter the microbiome, and microbiome changes can in turn affect disease activity. While findings are still evolving and not everyone with SLE shows the same microbial patterns, the overall picture supports the idea that microbiome-targeted strategies—such as diet quality, fiber intake, and medically guided approaches like probiotics or prebiotics in selected cases—may someday complement standard care. If you’re navigating lupus with your healthcare team, understanding the gut-immune connection can provide a foundation for discussing safe, individualized lifestyle and therapeutic options.

  • Joint pain and swelling (arthritis)
  • Skin rashes (e.g., malar/butterfly rash, photosensitivity)
  • Unexplained fatigue and low energy
  • Fever and general inflammation
  • Mouth or nasal ulcers
  • Hair loss (alopecia)
  • Chest pain or shortness of breath due to inflammation (pleuritis/pericarditis)
Test Your Gut Microbiome to Support Lupus Health Start Your Gut Microbiome Test for Lupus
innerbuddies gut microbiome testing

Systemic lupus erythematosus

This information is most relevant for people living with systemic lupus erythematosus (SLE)—especially those noticing recurring symptoms such as joint pain and swelling, persistent fatigue, fevers, rashes, mouth or nasal ulcers, or hair loss—because gut microbiome changes may influence the overall inflammatory tone that can affect immune dysregulation and disease activity. It can also be helpful for individuals trying to understand why symptoms sometimes flare in patterns that may relate to diet, medication use, infections, stress, or changes in digestion.

It’s also relevant for SLE patients who experience gastrointestinal sensitivity or suspect they have gut-barrier issues (for example, bloating, altered bowel habits, or intolerance to certain foods). The gut-immune connection is particularly important when intestinal permeability (“leaky gut”) and dysbiosis are discussed as potential contributors to chronic inflammation—processes that may interact with immune pathways involved in autoantibody production and regulatory T-cell balance.

Finally, this is useful for anyone managing SLE with their healthcare team who is interested in microbiome-informed, adjunct lifestyle strategies—such as improving diet quality and fiber intake, considering evidence-based prebiotic/probiotic discussions, or addressing factors that can reshape the microbiome safely alongside standard care. It may also apply to patients dealing with more systemic inflammatory symptoms (like pleuritis or pericarditis) who want a broader understanding of modifiable influences on immune function, while keeping expectations grounded in the fact that research is still evolving and individual responses can vary.

Systemic lupus erythematosus (SLE) is a relatively uncommon but well-recognized autoimmune condition, affecting an estimated ~0.1–0.3% of the population in many countries (roughly 1 to 3 people per 1,000). Prevalence varies by geography, ancestry, and study methods, with higher rates reported among Black/African American, Hispanic/Latino, and some Asian populations compared with White populations. Women of childbearing age account for the majority of cases, and disease incidence increases after puberty, which contributes to the overall observed burden across communities.

Although gut microbiome changes are an active research area in SLE, not every person with lupus shows the same gut microbial pattern. Still, studies using stool sequencing and functional profiling commonly report a higher prevalence of gut dysbiosis in SLE compared with healthy controls, along with alterations in microbial metabolites (including short-chain fatty acids) and immune-linked pathways. This gut–immune connection is clinically relevant because it may help explain why people with SLE can experience variable flares and symptoms such as fatigue, inflammatory joint pain, rashes, and mucosal ulcers—findings that reflect systemic immune activation.

Symptom patterns used in clinical practice also underscore how widespread the disease impact can be even when overall prevalence is modest. Common SLE manifestations—arthritis/joint swelling, photosensitive skin rashes, mouth/nasal ulcers, fever or inflammation, and pleuritis/pericarditis-related chest pain or shortness of breath—are reported across large patient cohorts, with frequencies depending on whether studies track early disease, active flares, or lifetime history. Taken together, SLE’s estimated prevalence of ~0.1–0.3% helps frame the condition as uncommon, while the commonality of multi-system symptoms highlights why immune dysregulation (potentially influenced by the gut microbiome and its metabolites) remains a major focus for supportive, individualized strategies alongside standard care.

Test Your Gut Microbiome to Support Lupus Health Start Your Gut Microbiome Test for Lupus
innerbuddies gut microbiome testing

Gut Microbiome and Lupus: How Your Microbiome Affects Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) involves immune misfiring, and research increasingly suggests the gut microbiome may influence how strongly that dysregulation develops. Many people with SLE show signs of gut dysbiosis—an imbalance in intestinal microbes—and changes in microbial functions that can affect immune pathways tied to inflammation and autoantibody production. Because gut bacteria help shape the body’s inflammatory tone, altered microbial communities may shift the immune system toward a more pro-inflammatory, autoimmunity-promoting state.

A key connection may be how gut microbes support the intestinal barrier and produce immunologically active metabolites. When the microbiome is disrupted, the gut lining may become more permeable (“leaky gut”), allowing microbial byproducts to interact more readily with immune cells. In parallel, microbes generate compounds such as short-chain fatty acids (SCFAs) and other bioactive metabolites that help regulate immune balance (including promoting protective regulatory T cells, or Tregs). Reduced or altered metabolite production can weaken these regulatory signals, potentially contributing to the chronic inflammation seen in SLE.

Importantly, the relationship appears bidirectional: SLE activity, systemic inflammation, and some medications (including corticosteroids and immunosuppressants) can also change the microbiome, while diet-related factors can further influence microbial composition and function. This gut–immune loop may help explain why SLE symptoms—such as joint pain and swelling, rashes, fatigue, mouth/nasal ulcers, and chest inflammation like pleuritis or pericarditis—can fluctuate alongside immune activity. While findings vary and microbiome patterns aren’t identical for every patient, microbiome-informed strategies (e.g., improving dietary fiber and overall diet quality, and considering medically guided prebiotic/probiotic approaches when appropriate) may complement standard care by supporting gut barrier health and immune regulation.

Test Your Gut Microbiome to Support Lupus Health Start Your Gut Microbiome Test for Lupus
innerbuddies gut microbiome testing

Gut Microbiome and Systemic lupus erythematosus

  • Gut dysbiosis that shifts immune set-point toward inflammation by altering microbial taxa and the functional pathways that drive cytokine production
  • Intestinal barrier dysfunction (“leaky gut”) where dysbiosis reduces mucus/tight-junction integrity, allowing microbial products (e.g., LPS) to access immune cells and amplify systemic immune activation
  • Reduced production of immunoregulatory metabolites—especially short-chain fatty acids (SCFAs) like butyrate—that normally promote regulatory T cells (Tregs) and dampen autoreactive immune responses
  • Altered bile acid metabolism that changes signaling through immune-regulatory receptors (e.g., FXR/TGR5), influencing inflammatory pathways and disease activity in SLE
  • Molecular mimicry and microbial-driven autoimmunity, where microbial antigens or modified microbial components may promote cross-reactive immune responses and autoantibody production
  • Immune cell training and cytokine skewing via microbial metabolites and ligands (e.g., effects on Th17/Treg balance), favoring pro-inflammatory subsets that contribute to SLE manifestations

In systemic lupus erythematosus (SLE), immune dysregulation appears to be influenced by the gut microbiome. When intestinal microbes become imbalanced (gut dysbiosis), the types of bacteria present and the functions they perform can shift the immune “set-point” toward chronic inflammation. This happens partly because dysbiotic communities alter signaling molecules that help shape cytokine production and immune cell behavior, including skewing the balance between pro-inflammatory and regulatory responses.

A major pathway is impaired intestinal barrier function, sometimes described as “leaky gut.” Normally, the gut lining and tight junctions limit exposure of immune cells to microbial products. With dysbiosis, the mucus layer and barrier integrity can weaken, allowing components such as lipopolysaccharide (LPS) and other microbial byproducts to interact more easily with immune cells. That increased exposure can amplify systemic immune activation—contributing to ongoing inflammatory activity that underlies many SLE features, from joint and skin involvement to organ inflammation.

Gut microbes also influence SLE through their metabolites and immune training signals. Many beneficial strains help produce immunoregulatory compounds—especially short-chain fatty acids (SCFAs) like butyrate—which support regulatory T cells (Tregs) and help restrain autoreactive immune responses. Dysbiosis may reduce these metabolites, weakening the checks on inflammation. In addition, altered bile acid metabolism can change signaling through immune-regulatory receptors such as FXR and TGR5, further affecting inflammatory pathways and disease activity. Finally, microbial-driven molecular mimicry and antigen exposure may promote cross-reactive immune responses and autoantibody production, reinforcing autoimmunity in genetically susceptible individuals.

Test Your Gut Microbiome to Support Lupus Health Start Your Gut Microbiome Test for Lupus
innerbuddies gut microbiome testing

Microbial patterns summary

In systemic lupus erythematosus (SLE), studies often report a “dysbiosis” pattern rather than one single organism consistently driving disease. Across cohorts, the gut community may show reduced diversity and shifts in relative abundance, with an imbalance between taxa associated with barrier-supporting, anti-inflammatory functions and those linked to inflammatory signaling. These changes can also involve altered microbial gene activity—especially pathways related to carbohydrate fermentation, bile acid handling, and immune-modulating metabolites—suggesting that it’s not only “who is there,” but what the microbes are doing that may influence immune tone.

A recurring theme is impaired gut barrier function alongside microbial compositional changes. When microbial communities become destabilized, they can affect the mucus layer and tight-junction integrity, increasing exposure of the immune system to bacterial components such as lipopolysaccharide (LPS) and other immunostimulatory products. This heightened microbial antigen exposure can promote a more pro-inflammatory cytokine environment, which may help explain correlations between gut alterations and systemic disease activity, including flares involving skin, joints, and serosal inflammation.

Metabolite output is another key feature frequently discussed in SLE-associated microbiome research. Beneficial fermentation products—particularly short-chain fatty acids (SCFAs) like butyrate—are often reduced or functionally altered in dysbiosis, which can weaken regulatory signaling that supports protective regulatory T cells (Tregs) and restrains autoreactive immune responses. In parallel, shifts in bile acid metabolism can modify immune-regulatory pathways through receptors such as FXR and TGR5, further shaping inflammatory cascades and potentially influencing autoantibody dynamics. Together, dysbiosis-driven changes in barrier function and immune-active metabolites may help create a gut–immune feedback loop that sustains or amplifies autoimmune activity.


Low beneficial taxa

  • Faecalibacterium prausnitzii (SCFA/butyrate-producer)
  • Roseburia spp. (butyrate-producers; gut barrier support)
  • Eubacterium rectale (butyrate-associated; Treg-supportive metabolites)
  • Anaerostipes spp. (SCFA production; anti-inflammatory potential)
  • Bifidobacterium spp. (often reduced; strengthens barrier and supports immune regulation)
  • Akkermansia muciniphila (mucus-layer support; may be altered in dysbiosis)


Elevated / overrepresented taxa

  • Ruminococcus gnavus (increased in SLE-like dysbiosis; pro-inflammatory carbohydrate fermentation products)
  • Blautia spp. (often increased when community shifts toward inflammatory metabolic profiles)
  • Prevotella spp. (frequently elevated in inflammatory gut communities; can drive inflammatory signaling via metabolites)
  • Enterococcus spp. (may be increased with barrier stress and pro-inflammatory effects; opportunistic expansion)
  • Escherichia-Shigella (often elevated with dysbiosis and higher exposure to immunostimulatory bacterial products)
  • Dialister spp. (tends to rise in dysbiotic states; associated with altered metabolite/immune tone)


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis and butyrate/acetate production (carbohydrate fermentation; supports Treg-mediated immune regulation and gut barrier health)
  • Bile acid metabolism and signaling (primary-to-secondary bile acid conversion; FXR/TGR5-mediated immune modulation)
  • Mucus layer and gut barrier integrity pathways (mucin turnover, tight-junction support, epithelial barrier maintenance; controls exposure to microbial products)
  • Lipopolysaccharide (LPS) and other immunostimulatory component exposure pathway (microbial antigen translocation/stimulation that drives pro-inflammatory cytokine production)
  • Carbohydrate fermentation to pro-inflammatory metabolites (e.g., altered carbohydrate utilization generating inflammatory immune-active metabolites)
  • Microbial metabolite generation affecting immune signaling (tryptophan/indole-related and other immune-modulating metabolite pathways that tune inflammation and autoimmunity)


Diversity note

In systemic lupus erythematosus (SLE), gut microbiome research commonly reports a dysbiosis pattern rather than a single consistent pathogen or signature organism. A recurring change is reduced microbial diversity, meaning the intestinal ecosystem often becomes less varied and more unstable. Alongside this overall decrease in diversity, studies frequently observe shifts in relative abundance across taxa—particularly an imbalance between microbes more associated with barrier-supporting, anti-inflammatory functions and those that tend to correlate with inflammatory signaling.

Beyond “who is there,” functional activity within the community often appears altered. Diversity changes can coincide with differences in microbial gene pathways involved in carbohydrate fermentation, bile acid handling, and the production of immune-active metabolites. These functional shifts matter because they can influence how strongly microbial products interact with the host immune system and how well the gut environment supports immune regulation, potentially contributing to the inflammatory tone seen in SLE.

SLE-associated diversity and compositional changes are also linked to gut barrier strain, which can increase exposure of the immune system to bacterial components. When communities are less diverse and metabolically imbalanced, beneficial outputs—especially short-chain fatty acids (SCFAs) such as butyrate—may be reduced or functionally altered. That change can weaken regulatory cues that normally help support protective regulatory T cells (Tregs), while altered bile acid metabolism may further modulate immune pathways, reinforcing a gut–immune feedback loop that can track with disease activity.


Test Your Gut Microbiome to Support Lupus Health Start Your Gut Microbiome Test for Lupus

Why generic solutions fail

  • Issue with generic solutions

    Generic solutions often fail in systemic lupus erythematosus (SLE) because the gut–immune relationship is not a simple “one bug causes inflammation” scenario. SLE is driven by immune dysregulation, and studies instead describe a broad dysbiosis pattern—reduced diversity and shifts in multiple taxa and, critically, in microbial functions. That means two people with SLE can have different microbial signatures and different impacts on immune pathways, so blanket probiotic or diet advice may not address the specific functional deficits (like altered carbohydrate fermentation, bile acid metabolism, or immune-modulating metabolite production) that influence inflammation and autoantibody activity.

    In addition, generic approaches may miss the barrier–metabolite axis that appears central to many SLE gut findings. Dysbiosis in SLE is often linked with impaired intestinal barrier integrity and increased exposure to immunostimulatory microbial products, which can amplify cytokine signaling and disease activity. If a “generic gut cleanse,” low-fiber plan, or nonspecific supplementation doesn’t support the mucus layer and tight-junction health—or doesn’t restore protective metabolites such as short-chain fatty acids (e.g., butyrate)—the immune-regulatory signals may remain weak, limiting any clinical benefit. Because metabolite outputs matter as much as community composition, interventions that only change relative abundances without improving functional output may underperform.

    Finally, typical one-size-fits-all strategies don’t adequately account for the bidirectional forces shaping the microbiome in SLE, including disease flares, systemic inflammation, and medication effects (notably corticosteroids and immunosuppressants). These factors can rapidly alter microbial ecology and metabolite pathways, meaning timing, tolerance, and adherence issues can strongly influence outcomes. Without medically guided personalization—taking into account diet, fiber tolerance, comorbidities, medication regimen, and the patient’s current inflammatory status—generic probiotics, prebiotics, or dietary templates often fail to produce consistent, durable improvements.

  • Common mistakes

    • Treating SLE gut issues as a single-organism problem instead of a dysbiosis-and-function problem (ignoring that multiple taxa and altered microbial pathways drive immune tone).
    • Using one-size-fits-all probiotic or “gut cleanse” protocols without matching the patient’s likely functional deficits (e.g., reduced SCFA/butyrate production, altered carbohydrate fermentation, or impaired bile-acid metabolism).
    • Overlooking the gut barrier angle (mucus layer and tight-junction integrity), assuming that changing community composition alone is enough even when LPS/antigen exposure remains elevated.
    • Focusing on relative abundance changes while neglecting microbial metabolite outputs (SCFAs, bile acid–mediated signaling, immune-modulating metabolites), which may be the more causally relevant factor.
    • Prescribing low-fiber or overly restrictive diets that fail to support SCFA-producing fermentation, thereby weakening Treg-supportive regulatory signaling.
    • Ignoring medication and disease-activity timing effects (e.g., corticosteroids and immunosuppressants, and flare-related shifts) that can rapidly change microbiome ecology and outcomes.
    • Not individualizing based on tolerance and comorbidities (IBS-like symptoms, renal involvement, constipation/diarrhea patterns), leading to poor adherence or unintended GI inflammation.
    • Skipping monitoring/feedback (GI symptoms, inflammatory markers, and treatment response) and continuing generic regimens despite lack of functional improvement.

What to do

  • General support strategies

    For systemic lupus erythematosus (SLE), gut-support strategies generally focus on reducing intestinal dysbiosis, strengthening gut barrier integrity, and supporting immune balance. Since many people with SLE show signs of altered microbial communities and shifts in microbial function, a diet that reliably supports a diverse microbiome can be a foundation. Emphasizing a high-fiber pattern (from vegetables, legumes, whole grains, and nuts) helps feed beneficial microbes and is associated with improved microbial diversity and gut barrier health. Adequate intake of micronutrients—along with an overall anti-inflammatory approach to food quality—may help lower the inflammatory “tone” that can influence immune activation and autoimmunity-related pathways.

    A second theme is supporting the metabolite environment produced by gut microbes. Helpful bacterial functions include generating short-chain fatty acids (SCFAs) and other immunologically active compounds that can promote immune regulation, including protective regulatory T cell (Treg) responses. When the microbiome is disrupted, these regulatory signals may be reduced, which can contribute to persistent inflammation. In addition to fiber, some patients may benefit from medically guided prebiotic strategies or probiotic formulations tailored to their tolerance and clinical situation—especially since SLE activity and medications (such as corticosteroids or immunosuppressants) can also affect the microbiome.

    Finally, because gut–immune interactions are bidirectional in SLE, general support also includes monitoring factors that can further destabilize gut health, such as persistent gastrointestinal symptoms, poor diet quality, and medication-related changes. Hydration, consistent meal patterns, and addressing constipation or diarrhea with clinician input can help reduce inflammatory stress on the gut lining. In parallel, maintaining standard SLE care while using gut-targeted approaches as complementary supports may help align intestinal barrier function and immune regulation with the broader goals of reducing flares and systemic inflammation.

  • Lifestyle recommendations

    • Follow an anti-inflammatory, high-fiber eating pattern (e.g., vegetables, legumes, whole grains, nuts/seeds) to support healthier gut microbiota and intestinal barrier function.
    • Aim for consistent micronutrient intake from food (e.g., adequate vitamin D, omega-3–rich foods if tolerated) and discuss any supplements with your clinician.
    • Prioritize gut-friendly foods while limiting potential irritants and pro-inflammatory dietary patterns (e.g., ultra-processed foods, excess added sugars, heavy alcohol use).
    • Reduce exposure to antibiotics when not medically necessary, and if antibiotics are prescribed, ask your care team about gut-recovery strategies.
    • Use medically guided prebiotic/probiotic approaches only when appropriate (especially if considering them, choose products thoughtfully and coordinate with your rheumatology team).
    • Maintain regular sleep, stress-management, and gentle physical activity as tolerated to help stabilize immune activation and overall inflammatory tone.

  • Nutrition recommendations

    • Prioritize a fiber-rich, plant-forward diet (e.g., legumes, oats, vegetables, berries, nuts, and whole grains) to support beneficial gut microbes and increase production of anti-inflammatory short-chain fatty acids (SCFAs).
    • Aim for omega-3 intake from fatty fish (salmon, sardines) or algae-based DHA/EPA, as omega-3s may help modulate immune inflammation and complement gut-immune regulation.
    • Choose minimally processed foods and limit added sugars and ultra-processed products to reduce dysbiosis and avoid immune-promoting inflammatory signaling.
    • Support gut barrier health by including a variety of polyphenol-rich foods (e.g., extra-virgin olive oil, berries, cocoa, green tea, spices like turmeric/ginger) which can promote beneficial microbial functions.
    • Consider prebiotic foods (e.g., garlic, onions, leeks, asparagus, bananas/plantains, chickpeas) and discuss medically appropriate, targeted probiotics with a clinician—especially if immunosuppressed—to avoid excess risk and improve gut microbial balance.
    • If you experience GI symptoms, practice individualized tolerance-based eating (e.g., adjusting high-FODMAP foods) rather than extreme restriction, to maintain adequate fiber for microbial recovery.

  • Supplement considerations

    For systemic lupus erythematosus (SLE), supplement support is best thought of as a way to promote a healthier gut–immune environment rather than as a stand-alone treatment. Research suggests that gut dysbiosis (imbalanced intestinal microbes) and altered microbial functions may influence inflammatory signaling and the development or regulation of autoimmunity. Supplements that support intestinal barrier integrity, reduce gut-level inflammation, and help restore microbial balance are often considered potential adjuncts—especially when diet alone isn’t enough to achieve consistent fiber intake or when symptoms suggest gut involvement (e.g., bloating, irregular stools, or nutrient absorption issues).

    A common area of interest involves metabolites produced by beneficial microbes, such as short-chain fatty acids (SCFAs). Because SCFAs (notably butyrate) support regulatory immune pathways and help maintain gut barrier function, some people consider fiber-focused “prebiotic” supplements (like inulin- or partially hydrolyzed fiber–type products) to encourage SCFA production. Probiotic or fermented-food–derived options may also be considered to increase microbial diversity and shift immune tone toward more regulatory activity. However, responses vary by strain, dose, and individual disease activity, and not every probiotic is appropriate for everyone—particularly during periods of active infection risk or severe immunosuppression.

    Given that SLE can require immunosuppressive therapy (and that medications themselves may affect the microbiome), supplement choices should be coordinated with a clinician. Some anti-inflammatory or antioxidant supplements (e.g., omega-3 fatty acids) are sometimes used to complement standard care, but they should not replace disease-modifying treatment. Safety considerations matter most for immunocompromised patients: avoid unnecessary high-risk supplements or unverified products, introduce new supplements gradually to monitor tolerability (especially GI side effects), and prioritize evidence-based dosing. Overall, supplement strategy should be individualized around current meds, current disease activity, and gut tolerance to reduce the chance of flares or adverse interactions.

  • Retesting / monitoring note

    For systemic lupus erythematosus (SLE), retesting related to gut microbiome health is typically considered when there are meaningful changes in disease activity, ongoing treatment, or diet that could plausibly shift the gut ecosystem. Because SLE activity and medications (particularly corticosteroids and other immunosuppressants) can alter microbial composition and immune signaling, retesting can help clarify whether prior gut findings persist, improve, or worsen. It’s often most useful to reassess after a stable period—commonly several weeks to a few months—once therapy and routine dietary patterns have settled, rather than immediately after short-term changes.

    Retesting is also recommended when there are new or worsening gastrointestinal or systemic symptoms (e.g., changes in bloating, stool consistency, fatigue, or flare-like patterns) that may correlate with gut barrier function and microbial metabolite shifts. If the goal is to monitor the gut–immune loop (such as markers related to dysbiosis, microbial functional pathways, or patterns linked to inflammatory tone), spacing retests at an interval that allows biology to respond—often aligned with a clinical follow-up cadence—is more informative than frequent testing. In many cases, clinicians may pair gut retesting with objective SLE assessment (symptoms and relevant lab/immunologic markers) to interpret whether microbial changes track with inflammation and autoantibody activity.

    Finally, any retesting plan should be coordinated with prior results and the testing strategy used (for example, whether you’re evaluating taxonomic profiles, functional signatures, or gut-barrier–related indicators). If an intervention such as increasing fiber, adjusting dietary patterns, or medically guided prebiotic/probiotic approaches is introduced, retesting can be scheduled to evaluate response and guide next steps. To improve comparability across time, it helps to standardize sample collection methods, account for antibiotic or recent flare-related medication adjustments, and document diet changes, timing, and symptom status before each retest.

The importance of gut microbiome testing

  • Why testing matters

    In systemic lupus erythematosus (SLE), the immune system can become dysregulated, and growing evidence suggests the gut microbiome may influence how strongly that dysregulation develops and how it fluctuates over time. Gut microbiome testing can help identify whether someone shows signs of dysbiosis—such as imbalances in beneficial versus potentially inflammatory microbial communities or shifts in microbial functions—that may correlate with immune activation, inflammation, and autoimmune activity. Because SLE involves a gut–immune feedback loop, recognizing a patient’s baseline microbial pattern can be useful for making sense of symptom variability, including flare-associated changes in fatigue, rashes, joint pain, and mucosal ulcers.

    Testing also matters because the microbiome doesn’t just change “who is there,” it changes what the microbes do—especially the production of immunologically relevant metabolites. Many microbial compounds (like short-chain fatty acids and other signaling molecules) support intestinal barrier integrity and promote immune tolerance through pathways that help generate or maintain regulatory T cells (Tregs). When microbial metabolite output is reduced or altered, the gut lining may become more permeable and immune cells may receive stronger pro-inflammatory signals. Microbiome testing can therefore help clinicians and patients target likely functional gaps rather than relying only on general diet or supplement advice.

    Finally, gut microbiome composition and function are bidirectionally affected by SLE activity and by treatments such as corticosteroids and immunosuppressants, as well as by diet, stress, and overall health behaviors. For this reason, testing can support more personalized, medically informed approaches—such as diet quality optimization, fiber-focused strategies, or carefully selected prebiotic/probiotic interventions—while tracking whether changes align with better gut barrier markers and improved inflammatory control. While microbiome findings don’t diagnose SLE on their own, they can add actionable context that complements standard care and may help guide supportive strategies aimed at stabilizing the gut–immune axis.

  • How InnerBuddies helps

    For systemic lupus erythematosus (SLE), InnerBuddies can help by giving insight into whether your gut microbiome shows signs of dysbiosis—an imbalance in the types of microbes and their overall functional activity. Because SLE is influenced by an immune “gut–immune loop,” the test may help identify patterns that are more commonly associated with immune activation and inflammation. For many people, tracking these baseline microbial characteristics can also offer context for symptom variability (such as fatigue, joint pain, rashes, and mucosal ulcers), since gut-related immune signaling can shift over time.

    InnerBuddies looks beyond simple “who is present” to focus on what the microbiome is doing—particularly the metabolic functions that can affect intestinal barrier integrity and immune regulation. In SLE, changes in microbial metabolite production (including compounds like short-chain fatty acids and other immunomodulatory signals) may contribute to a more permeable gut barrier and altered immune tolerance. By highlighting functional gaps or imbalances, InnerBuddies can support more targeted, mechanism-informed lifestyle or dietary strategies aimed at strengthening gut barrier health and encouraging anti-inflammatory immune pathways (such as regulatory T cell activity).

    Importantly, the gut microbiome is bidirectionally influenced by SLE activity, systemic inflammation, and treatments (including corticosteroids and immunosuppressants), as well as diet and stress. InnerBuddies can therefore be used as a personalized starting point to guide medically appropriate prebiotic/probiotic or nutrition adjustments, and to monitor whether changes in your gut ecosystem align with improvements in inflammatory control and overall wellbeing. While microbiome testing cannot diagnose SLE alone, it can add actionable, individualized context that complements standard care and supports a more holistic approach to managing the disease.

Medical Evidence

  • Scientific evidence level

    2 [weak; mostly observational with limited causal/interventional evidence and no validated clinical utility]

  • Clinical relevance note

    Current clinical relevance is limited. There is evidence consistent with gut dysbiosis in SLE and biologically plausible pathways connecting microbial communities/metabolites to autoimmune regulation. However, the human signal is not sufficiently consistent or reproducible to support diagnostic use, and the effect sizes and directionality across studies are variable. Most studies are also difficult to interpret because SLE patients commonly receive medications that can profoundly alter microbiome composition, and disease activity itself can change gut physiology and sampling conditions.

    From a causal and intervention standpoint, the gap is the critical one: there is no strong human evidence that altering the gut microbiome causally improves SLE in a sustained and clinically meaningful way. Even where correlations with disease activity exist, they do not establish that microbiome features are driving disease rather than reflecting it. Until larger, well-controlled longitudinal studies (with careful medication/diet control and standardized methodologies) and adequately powered RCTs with clinically relevant endpoints are available, microbiome measurement should be considered research-oriented rather than decision-support in routine practice.

Title Journal Year Link
The gut microbiome in systemic lupus erythematosus: a systematic review Frontiers in Immunology 2020 View →
Alterations in the gut microbiome and immune responses in lupus patients Nature Communications 2017 View →
Gut microbiome dysbiosis is associated with disease activity and lupus nephritis Arthritis & Rheumatology 2016 View →
Microbiome-derived IL-21-producing Th cells in lupus-prone mice and their modulation by antibiotic treatment Nature Communications 2016 View →
Microbiota and lupus: the role of segmented filamentous bacteria in the induction of IL-17 and lupus-like autoimmunity Journal of Immunology 2012 View →

Frequently Asked Questions

    ¿Qué es la SLE y cómo podría influir el microbioma intestinal?
    La SLE es una enfermedad autoinmune. El microbioma intestinal puede influir en la regulación inmunitaria y la inflamación, afectando potencialmente la actividad de la enfermedad. Es un área de investigación; no es un diagnóstico.
    ¿La disbiosis intestinal puede desencadenar brotes de SLE?
    Algunos estudios muestran una asociación, pero es variable; es uno de varios factores y no una causa comprobada de brotes.
    ¿Qué síntomas intestinales pueden aparecer en la SLE?
    Dolor y edema en las articulaciones, erupciones en la piel, fatiga, fiebre/ inflamación, úlceras bucales o nasales, caída del cabello, dolor en el pecho o falta de aliento por inflamación.
    ¿Cómo puede la dieta afectar el microbioma en la SLE?
    La calidad de la dieta y la ingesta de fibra pueden influir en las bacterias intestinales y la barrera intestinal; puede apoyar el equilibrio inmunológico y el bienestar. Habla con tu médico sobre cambios.
    ¿Existen bacterias específicas asociadas a la SLE?
    Se han observado patrones (p. ej., mayor Ruminococcus gnavus, menor Faecalibacterium prausnitzii), pero varían entre personas.
    ¿Qué es la 'pared intestinal porosa' y por qué importa en la SLE?
    Una permeabilidad intestinal aumentada puede permitir que productos microbianos interactúen con células inmunitarias y aumenten la inflamación. Es una hipótesis mecanicista.
    ¿Qué son los ácidos grasos de cadena corta (SCFA) y por qué son importantes?
    Los SCFA como el butirato ayudan a la barrera intestinal y a las células T reguladoras; una producción reducida puede asociarse con inflamación en algunos estudios.
    ¿Debería hacerme un test del microbioma si tengo SLE?
    El test puede aportar contexto sobre la función intestinal, pero no diagnostica la SLE y no reemplaza la atención estándar. Hablarlo con un profesional de la salud.
    ¿Qué estrategias centradas en el microbioma se discuten?
    Mejorar la calidad de la dieta, aumentar la ingesta de fibra y, en casos seleccionados, prebióticos/probióticos guiados por un médico.
    ¿Son seguros los probióticos para las personas con SLE?
    En general son seguros para muchos, pero la seguridad depende de la salud individual y de la medicación; consultar con el equipo de atención.
    ¿Los fármacos para la SLE afectan el microbioma?
    Sí. Los corticosteroides y los inmunosupresores pueden influir en las bacterias intestinales; los planes de tratamiento deben considerar esto.
    ¿Qué hacer si un test muestra disbiosis?
    Interpretar los resultados con tu médico y considerar cambios en la dieta o en la fibra; evitar el automedicarse.
    ¿Qué tan fiables son los tests del microbioma?
    Los tests varían en lo que miden (composición vs función). Ofrecen señales útiles pero no son un diagnóstico por sí solos; se necesita contexto clínico.
    ¿Con qué frecuencia debe repetirse un test del microbioma?
    La frecuencia depende del contexto clínico; consultar con tu médico para definir el momento adecuado.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -